159 related articles for article (PubMed ID: 23086421)
1. Nuclear PI-PLC β1 and Myelodysplastic syndromes: from bench to clinics.
Mongiorgi S; Follo MY; Clissa C; Giardino R; Fini M; Manzoli L; Ramazzotti G; Fiume R; Finelli C; Cocco L
Curr Top Microbiol Immunol; 2012; 362():235-45. PubMed ID: 23086421
[TBL] [Abstract][Full Text] [Related]
2. Nuclear inositide signaling in myelodysplastic syndromes.
Follo MY; Mongiorgi S; Finelli C; Clissa C; Ramazzotti G; Fiume R; Faenza I; Manzoli L; Martelli AM; Cocco L
J Cell Biochem; 2010 Apr; 109(6):1065-71. PubMed ID: 20058233
[TBL] [Abstract][Full Text] [Related]
3. Nuclear phospholipase C β1 signaling, epigenetics and treatments in MDS.
Follo MY; Marmiroli S; Faenza I; Fiume R; Ramazzotti G; Martelli AM; Gobbi P; McCubrey JA; Finelli C; Manzoli FA; Cocco L
Adv Biol Regul; 2013 Jan; 53(1):2-7. PubMed ID: 23058275
[TBL] [Abstract][Full Text] [Related]
4. Nuclear phospholipase C beta1, regulation of the cell cycle and progression of acute myeloid leukemia.
Cocco L; Manzoli L; Palka G; Martelli AM
Adv Enzyme Regul; 2005; 45():126-35. PubMed ID: 16024064
[TBL] [Abstract][Full Text] [Related]
5. Activation of nuclear inositide signalling pathways during erythropoietin therapy in low-risk MDS patients.
Follo MY; Mongiorgi S; Clissa C; Paolini S; Martinelli G; Martelli AM; Fioravanti G; Manzoli L; Finelli C; Cocco L
Leukemia; 2012 Dec; 26(12):2474-82. PubMed ID: 22596089
[TBL] [Abstract][Full Text] [Related]
6. Nuclear PI-PLCβ1 and myelodysplastic syndromes: genetics and epigenetics.
Follo MY; Mongiorgi S; Finelli C; Piazzi M; Faenza I; Ramazzotti G; Santi P; McCubrey JA; Martelli AM; Cocco L
Curr Pharm Des; 2012; 18(13):1751-4. PubMed ID: 22352752
[TBL] [Abstract][Full Text] [Related]
7. Inositide-specific phospholipase c beta1 gene deletion in the progression of myelodysplastic syndrome to acute myeloid leukemia.
Lo Vasco VR; Calabrese G; Manzoli L; Palka G; Spadano A; Morizio E; Guanciali-Franchi P; Fantasia D; Cocco L
Leukemia; 2004 Jun; 18(6):1122-6. PubMed ID: 15085153
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment.
Follo MY; Russo D; Finelli C; Mongiorgi S; Clissa C; Filì C; Colombi C; Gobbi M; Manzoli L; Piazzi M; Martelli AM; Cocco L
Leukemia; 2012 May; 26(5):943-50. PubMed ID: 22033492
[TBL] [Abstract][Full Text] [Related]
9. Physiology and pathology of nuclear phospholipase C β1.
Cocco L; Follo MY; Faenza I; Fiume R; Ramazzotti G; Weber G; Martelli AM; Manzoli FA
Adv Enzyme Regul; 2011; 51(1):2-12. PubMed ID: 21035488
[TBL] [Abstract][Full Text] [Related]
10. Nuclear Inositide Signaling Via Phospholipase C.
Ratti S; Mongiorgi S; Ramazzotti G; Follo MY; Mariani GA; Suh PG; McCubrey JA; Cocco L; Manzoli L
J Cell Biochem; 2017 Aug; 118(8):1969-1978. PubMed ID: 28106288
[TBL] [Abstract][Full Text] [Related]
11. Nuclear inositide signaling: an appraisal of phospholipase C beta 1 behavior in myelodysplastic and leukemia cells.
Cocco L; Follo MY; Faenza I; Bavelloni A; Billi AM; Martelli AM; Manzoli L
Adv Enzyme Regul; 2007; 47():2-9. PubMed ID: 17335878
[No Abstract] [Full Text] [Related]
12. Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia.
Follo MY; Finelli C; Clissa C; Mongiorgi S; Bosi C; Martinelli G; Baccarani M; Manzoli L; Martelli AM; Cocco L
J Clin Oncol; 2009 Feb; 27(5):782-90. PubMed ID: 19114693
[TBL] [Abstract][Full Text] [Related]
13. Advances in MDS/AML and inositide signalling.
De Stefano A; Marvi MV; Fazio A; McCubrey JA; Suh PG; Ratti S; Ramazzotti G; Manzoli L; Cocco L; Follo MY
Adv Biol Regul; 2023 Jan; 87():100955. PubMed ID: 36706610
[TBL] [Abstract][Full Text] [Related]
14. Inositide-dependent signaling pathways as new therapeutic targets in myelodysplastic syndromes.
Mongiorgi S; Finelli C; Yang YR; Clissa C; McCubrey JA; Billi AM; Manzoli L; Suh PG; Cocco L; Follo MY
Expert Opin Ther Targets; 2016 Jun; 20(6):677-87. PubMed ID: 26610046
[TBL] [Abstract][Full Text] [Related]
15. Nuclear phospholipase C in biological control and cancer.
Ramazzotti G; Faenza I; Follo MY; Fiume R; Piazzi M; Giardino R; Fini M; Cocco L
Crit Rev Eukaryot Gene Expr; 2011; 21(3):291-301. PubMed ID: 22111715
[TBL] [Abstract][Full Text] [Related]
16. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
17. Synergistic induction of PI-PLCβ1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes.
Follo MY; Finelli C; Mongiorgi S; Clissa C; Chiarini F; Ramazzotti G; Paolini S; Martinelli G; Martelli AM; Cocco L
Leukemia; 2011 Feb; 25(2):271-80. PubMed ID: 21109771
[TBL] [Abstract][Full Text] [Related]
18. Nuclear phosphoinositide specific phospholipase C (PI-PLC)-beta 1: a central intermediary in nuclear lipid-dependent signal transduction.
Martelli AM; Fiume R; Faenza I; Tabellini G; Evangelista C; Bortul R; Follo MY; Falà F; Cocco L
Histol Histopathol; 2005 Oct; 20(4):1251-60. PubMed ID: 16136505
[TBL] [Abstract][Full Text] [Related]
19. Nuclear phospholipase C: involvement in signal transduction.
Manzoli L; Martelli AM; Billi AM; Faenza I; Fiume R; Cocco L
Prog Lipid Res; 2005 Jul; 44(4):185-206. PubMed ID: 15896848
[TBL] [Abstract][Full Text] [Related]
20. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]